Media stories about Aeglea BioTherapeutics (NASDAQ:AGLE) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aeglea BioTherapeutics earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.6076472422215 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Aeglea BioTherapeutics (NASDAQ AGLE) traded down 0.49% during midday trading on Friday, hitting $4.09. 55,427 shares of the company traded hands. The stock has a 50 day moving average of $3.35 and a 200-day moving average of $5.11. Aeglea BioTherapeutics has a 52 week low of $2.81 and a 52 week high of $10.34. The stock’s market capitalization is $67.29 million.

AGLE has been the topic of several research reports. Zacks Investment Research raised shares of Aeglea BioTherapeutics from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a report on Thursday, August 3rd. ValuEngine raised shares of Aeglea BioTherapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, TheStreet lowered shares of Aeglea BioTherapeutics from a “c-” rating to a “d+” rating in a report on Friday, May 26th.

ILLEGAL ACTIVITY WARNING: This article was reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at

Aeglea BioTherapeutics Company Profile

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.